The present disclosure provides fusion proteins that specifically inhibit transforming growth factor-β (TGF-β) signaling in CD4+ helper T cells, and engineered CD4+ helper T cells that are deficient in TGF-β signaling, to counteract tumor-induced immune tolerance and promote anti-tumor immunity. The fusion proteins and engineered CD4+ helper T cells of the present technology are useful in methods for treating cancer, and enhancing the efficacy of other therapeutic agents against refractory cancer cells.
A|X Armani Exchange
Sales Associate
Aladdin Technology Company
Kyc Auditor
Huijia Nursing Home
Research Specialist
Kung Fu Tea Aug 2018 - Dec 2018
Barista
Gold Coast Hotel & Casino Jan 2017 - Dec 2018
Server
Education:
University of Utah - David Eccles School of Business 2017 - 2020
Master of Science, Masters, Finance
University of Nevada - Las Vegas
Bachelors, Management, Hospitality
Skills:
Responsible Service of Alcohol Multitasking Hospitality Service Bilingualism Bilingual Communications Great Personality Skilled Multi Tasker Training and Development Mandarin Auditing Retail Sales Customer Service